公开(公告)号：US20220033784A1

公开(公告)日：2022-02-03

申请号：US17371206

申请日：2021-07-09

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Michael Dale Eisenbraun ,  Clare Lees ,  Jeremy Shawn Myers ,  James Travis Patterson

IPC: C12N7/00 ,  C07K14/55 ,  A61K35/768 ,  A61P35/00

Abstract: The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.

公开(公告)号：US20240209061A1

公开(公告)日：2024-06-27

申请号：US17908822

申请日：2021-03-05

Applicant: Pfizer Inc.

Inventor： Eric Matthew Bennett ,  Christina Hwei-Lin Eng ,  Laura Lin Lohse ,  Lidia Mosyak ,  Jeremy Shawn Myers ,  Mohosin Sarkar ,  Hayretin Rafet Yumerefendi

IPC: C07K14/705 ,  A61K31/5025 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K14/70532 ,  A61K31/5025 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/94 ,  C07K2319/30

Abstract: The present invention provides for CD80-Fc fusion proteins that have therapeutic and diagnostic use, and methods for making thereof. The present invention further relates to variant CD80 polypeptides. The present invention also provides for CD80-Fc fusion proteins for use in the treatment of cancer.